Jootar, S2009-05-272009-05-271989-12-01Jootar S. Interferon alpha-2a to control thrombocytosis in chronic myelogenous leukemia and essential thrombocythemia. Asian Pacific Journal of Allergy and Immunology. 1989 Dec; 7(2): 103-5http://imsear.searo.who.int/handle/123456789/36971Published by the Allergy and Immunology Society of Thailand.Four patients with chronic myelogenous leukemia and thrombocytosis and one patient with essential thrombocythemia were treated with purified recombinant human interferon alpha-2a (IFN-alpha 2a). Significant decline in platelet counts, from a mean ( +/- SE) of 1.396 +/- 0.265 x 10(6)/mm3 to a mean of 0.396 +/- 0.04 x 10(6)/mm3 (p less than 0.05), was observed in all patients. The platelet count remained normal for 15, 21 and 30 days after discontinuation of IFN-alpha 2a in 3 patients. In 2 patients the platelet count began to rise slowly two weeks after discontinuation of IFN-alpha 2a. Our preliminary observations suggest that purified recombinant human IFN-alpha 2a may effectively control progressive thrombocytosis in advanced chronic myelogenous leukemia and essential thrombocythemia.engAdultAgedFemaleHumansInterferon Alfa-2a --therapeutic useInterferon Type I, Recombinant --therapeutic useLeukemia, Myelogenous, Chronic, BCR-ABL Positive --complicationsMaleMiddle AgedPlatelet Count --drug effectsThrombocytosis --etiologyJournal Article